MH002, the first Optimized Consortia Therapeutic in Clinical Development for Ulcerative Colitis, Manufactured as Single Drug Substance

Time: 11:20 am
day: Track A - Afternoon - Day One


  • MH002 is an optimized combination of 6 commensal bacteria, rationally designed to target multiple key disease-modifying mechanisms of action in IBD
  • MH002 is in clinical development in a Phase 1b/2a study in mild-to-moderate UC patients, with a lead extension program ongoing
  • First application of MRM Health’s Microbiome Optimization TechnologyTM, anticipated to outperform conventional consortia with increased potency, engraftment, and resilience, and manufactured through its breakthrough proprietary scalable and cost-effective single drug substance technology